Stock events for CG Oncology, Inc. (CGON)
CG Oncology went public in January 2024, offering 20 million shares at $19.00 per share, followed by a secondary offering of 8 million shares at $28.00 per share in December 2024. The stock has experienced a 52-week high of $63.58 and a 52-week low of $14.80. CGON's shares have surged by 98.78% and 112.8% over the past six months, driven by the early completion of patient enrollment in the Phase III PIVOT-006 study and progress towards a Biologics License Application (BLA) submission for cretostimogene in high-risk NMIBC. In February 2026, CG Oncology reported its 2025 results, with revenues of $4.0 million and a net loss of $161.0 million, and announced a strengthened cash position of approximately $903.0 million as of February 26, 2026, which is expected to fund operations into the first half of 2029.
Demand Seasonality affecting CG Oncology, Inc.’s stock price
As a clinical-stage biopharmaceutical company without commercialized products, CG Oncology, Inc. does not have discernible demand seasonality. The company's revenue generation is currently modest and primarily driven by its ongoing investment in research and development and equity raises to fund its programs.
Overview of CG Oncology, Inc.’s business
CG Oncology, Inc. is a clinical biopharmaceutical company focused on developing bladder-sparing therapeutics for bladder cancer, operating within the biotechnology industry. Its lead product candidate, cretostimogene grenadenorepvec, is an oncolytic immunotherapy designed to selectively infect and lyse tumor cells, activating an anti-tumor immune response. Cretostimogene is in Phase III clinical trial BOND-003 assessing cretostimogene as a monotherapy for high-risk Bacillus Calmette Guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients. In December 2023, cretostimogene received FDA Fast Track and Breakthrough Therapy Designations for high-risk BCG-unresponsive NMIBC with carcinoma in situ. Recent data from BOND-003 Cohort C showed a 75.5% complete response rate in over 110 BCG-unresponsive CIS patients, with approximately 90% of 12-month responders remaining in complete response at 24 months. CORE-001 is a Phase II clinical trial evaluating cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients. PIVOT-006 is a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene as monotherapy in patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT). CORE-002 is investigating cretostimogene in combination with nivolumab for muscle invasive bladder cancer patients. CORE-008 is a Phase II clinical trial for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients.
CGON’s Geographic footprint
CG Oncology, Inc. is headquartered in Irvine, California, United States. The company develops and commercializes its therapeutics for patients with bladder cancer in the United States.
CGON Corporate Image Assessment
CG Oncology has maintained a strong brand reputation, driven by positive clinical trial results and regulatory designations. The FDA granted Fast Track and Breakthrough Therapy Designations to cretostimogene in December 2023 for high-risk BCG-unresponsive NMIBC. Cretostimogene has demonstrated encouraging durability and response data in late-stage studies. Analysts have a strong consensus, with 15 analysts issuing "Buy" ratings and an average target price of $80.43. There have been no reported events negatively affecting CG Oncology's reputation in the past year.
Ownership
CG Oncology, Inc. has a mixed ownership structure comprising institutional, retail, and individual investors. As of February 27, 2026, the company has 346 institutional owners and shareholders holding a total of 81,871,172 shares. Major institutional shareholders include Vanguard Group Inc, Decheng Capital LLC, Wellington Management Group Llp, BlackRock, Inc., Fmr Llc, Price T Rowe Associates Inc /md/, State Street Corp, Foresite Capital Management VI LLC, Rtw Investments, Lp, and VTSMX - Vanguard Total Stock Market Index Fund Investor Shares. Other significant institutional holders include Longitude Capital Management Co., LLC, TCG Crossover Management, LLC, and ORI Capital Limited. Approximately 38.98% to 53.68% of the company's stock is owned by Institutional Investors, 10.61% by Insiders, and 14.70% to 35.71% by Public Companies and Individual Investors.
